Chemotherapy for Malignant Pleural Mesothelioma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-06

AUTHORS

Linda L Garland

ABSTRACT

Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy. More... »

PAGES

181-188

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6

DOI

http://dx.doi.org/10.1007/s11864-011-0152-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007072178

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21468683


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precision Medicine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garland", 
        "givenName": "Linda L", 
        "id": "sg:person.01322145005.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-010-9553-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005827538", 
          "https://doi.org/10.1007/s12032-010-9553-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-06", 
    "datePublishedReg": "2011-04-06", 
    "description": "Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11864-011-0152-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022080", 
        "issn": [
          "1527-2729", 
          "1534-6277"
        ], 
        "name": "Current Treatment Options in Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "frontline therapy", 
      "fit patients", 
      "MPM patients", 
      "clinical trials", 
      "single agent", 
      "standard frontline therapy", 
      "less fit patients", 
      "second-line chemotherapy", 
      "good performance status", 
      "randomized clinical trials", 
      "single chemotherapy agent", 
      "malignant pleural mesothelioma", 
      "quality of life", 
      "platinum doublets", 
      "line chemotherapy", 
      "performance status", 
      "survival benefit", 
      "platinum regimens", 
      "pleural mesothelioma", 
      "chemotherapy agents", 
      "prognostic scale", 
      "patients", 
      "chemotherapeutic agents", 
      "prior exposure", 
      "therapy", 
      "chemotherapy", 
      "second line", 
      "trials", 
      "agents", 
      "exposure", 
      "viable option", 
      "regimens", 
      "mesothelioma", 
      "retreatment", 
      "symptoms", 
      "progression", 
      "enrollment", 
      "additional means", 
      "benefits", 
      "status", 
      "options", 
      "frontline", 
      "MPM", 
      "long time", 
      "life", 
      "combination", 
      "quality", 
      "lines", 
      "time", 
      "scale", 
      "means", 
      "doublet"
    ], 
    "name": "Chemotherapy for Malignant Pleural Mesothelioma", 
    "pagination": "181-188", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007072178"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11864-011-0152-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21468683"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11864-011-0152-6", 
      "https://app.dimensions.ai/details/publication/pub.1007072178"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11864-011-0152-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11864-011-0152-6'


 

This table displays all metadata directly associated to this object as RDF triples.

143 TRIPLES      22 PREDICATES      85 URIs      76 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11864-011-0152-6 schema:about N33cb3e0b268847a89a44db14d1b02bc9
2 N42ea498268774db2beb0250bc33b7989
3 N5f6605b624564fb68e09321c85accfe7
4 N9d4258e9fc4f486688d3dc61b81f1108
5 Nbf2f5fb221564d3fb52a77714786e8a8
6 Neded2e8c56bc42cda7046693d22831be
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author N2e24f415767b447391b988b2203b3a75
10 schema:citation sg:pub.10.1007/s12032-010-9553-9
11 schema:datePublished 2011-04-06
12 schema:datePublishedReg 2011-04-06
13 schema:description Opinion statementAll MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N2eadaae908124b44987eeaf554d82222
18 Nd9bcb309a8f44d9bab2608708fc3c906
19 sg:journal.1022080
20 schema:keywords MPM
21 MPM patients
22 additional means
23 agents
24 benefits
25 chemotherapeutic agents
26 chemotherapy
27 chemotherapy agents
28 clinical trials
29 combination
30 doublet
31 enrollment
32 exposure
33 fit patients
34 frontline
35 frontline therapy
36 good performance status
37 less fit patients
38 life
39 line chemotherapy
40 lines
41 long time
42 malignant pleural mesothelioma
43 means
44 mesothelioma
45 options
46 patients
47 performance status
48 platinum doublets
49 platinum regimens
50 pleural mesothelioma
51 prior exposure
52 prognostic scale
53 progression
54 quality
55 quality of life
56 randomized clinical trials
57 regimens
58 retreatment
59 scale
60 second line
61 second-line chemotherapy
62 single agent
63 single chemotherapy agent
64 standard frontline therapy
65 status
66 survival benefit
67 symptoms
68 therapy
69 time
70 trials
71 viable option
72 schema:name Chemotherapy for Malignant Pleural Mesothelioma
73 schema:pagination 181-188
74 schema:productId N9ac2ea34bece4b6491a47535869a5223
75 Na0e83d044e2e4cc6b05047e8058a9b41
76 Nbfec861f62a34ce69a7244cd29c9bb54
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007072178
78 https://doi.org/10.1007/s11864-011-0152-6
79 schema:sdDatePublished 2022-05-10T10:01
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher Nf69a0efa813f48fcab74bb673181fcbb
82 schema:url https://doi.org/10.1007/s11864-011-0152-6
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N2e24f415767b447391b988b2203b3a75 rdf:first sg:person.01322145005.35
87 rdf:rest rdf:nil
88 N2eadaae908124b44987eeaf554d82222 schema:issueNumber 2
89 rdf:type schema:PublicationIssue
90 N33cb3e0b268847a89a44db14d1b02bc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antineoplastic Agents
92 rdf:type schema:DefinedTerm
93 N42ea498268774db2beb0250bc33b7989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Mesothelioma
95 rdf:type schema:DefinedTerm
96 N5f6605b624564fb68e09321c85accfe7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Antineoplastic Combined Chemotherapy Protocols
98 rdf:type schema:DefinedTerm
99 N9ac2ea34bece4b6491a47535869a5223 schema:name pubmed_id
100 schema:value 21468683
101 rdf:type schema:PropertyValue
102 N9d4258e9fc4f486688d3dc61b81f1108 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Humans
104 rdf:type schema:DefinedTerm
105 Na0e83d044e2e4cc6b05047e8058a9b41 schema:name doi
106 schema:value 10.1007/s11864-011-0152-6
107 rdf:type schema:PropertyValue
108 Nbf2f5fb221564d3fb52a77714786e8a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Precision Medicine
110 rdf:type schema:DefinedTerm
111 Nbfec861f62a34ce69a7244cd29c9bb54 schema:name dimensions_id
112 schema:value pub.1007072178
113 rdf:type schema:PropertyValue
114 Nd9bcb309a8f44d9bab2608708fc3c906 schema:volumeNumber 12
115 rdf:type schema:PublicationVolume
116 Neded2e8c56bc42cda7046693d22831be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Pleural Neoplasms
118 rdf:type schema:DefinedTerm
119 Nf69a0efa813f48fcab74bb673181fcbb schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
122 schema:name Medical and Health Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
125 schema:name Oncology and Carcinogenesis
126 rdf:type schema:DefinedTerm
127 sg:journal.1022080 schema:issn 1527-2729
128 1534-6277
129 schema:name Current Treatment Options in Oncology
130 schema:publisher Springer Nature
131 rdf:type schema:Periodical
132 sg:person.01322145005.35 schema:affiliation grid-institutes:grid.134563.6
133 schema:familyName Garland
134 schema:givenName Linda L
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35
136 rdf:type schema:Person
137 sg:pub.10.1007/s12032-010-9553-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005827538
138 https://doi.org/10.1007/s12032-010-9553-9
139 rdf:type schema:CreativeWork
140 grid-institutes:grid.134563.6 schema:alternateName Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA
141 schema:name Arizona Cancer Center, Suite 1969H, 1515 N. Campbell Ave., 85724, Tucson, AZ, USA
142 Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
143 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...